Related Experiment Video
Updated: Jun 7, 2026

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
Published on: June 18, 2020
A multi-marker approach to predict incident CKD and microalbuminuria
Caroline S Fox1, Philimon Gona, Martin G Larson
1National Heart, Lung, and Blood Institute's Framingham Heart Study, 73 Mount Wayte Avenue, Suite #2, Framingham, MA 01702, USA. foxca@nhlbi.nih.gov
Insights
New biomarkers like homocysteine and aldosterone can help identify individuals at risk for chronic kidney disease (CKD) and microalbuminuria (MA) beyond traditional factors.
Area of Science:
- Nephrology
- Biomarkers
- Epidemiology
Background:
- Traditional risk factors are insufficient for predicting chronic kidney disease (CKD) incidence.
- Early identification of CKD and microalbuminuria (MA) is crucial for timely intervention.
Purpose of the Study:
- To evaluate a multi-marker panel of circulating biomarkers for predicting incident CKD and MA.
- To assess the incremental predictive utility of these biomarkers beyond established risk factors.
Main Methods:
- Utilized data from 2345 participants in the Framingham Offspring Study.
- Measured seven biomarkers: C-reactive protein, aldosterone, renin, B-type natriuretic peptide (BNP), plasminogen-activator inhibitor type 1, fibrinogen, and homocysteine.
- Defined CKD and MA at follow-up and employed multivariable logistic regression and risk reclassification analyses.
Main Results:
- The multi-marker panel was significantly associated with incident CKD and MA.
- Serum homocysteine and aldosterone were independently associated with CKD incidence.
- Aldosterone, BNP, and homocysteine showed significant associations with incident MA.
- Biomarkers improved risk prediction, evidenced by enhanced c-statistics and a 7% increase in net risk reclassification.
Conclusions:
- Circulating homocysteine, aldosterone, and BNP provide valuable incremental information for predicting incident CKD and MA.
- This multi-marker approach enhances risk stratification beyond traditional factors.
- Further research may integrate these biomarkers into clinical risk assessment tools for kidney disease.
Abstract:
Traditional risk factors do not adequately identify individuals at risk for CKD. We related a multi-marker panel consisting of the following seven circulating biomarkers to the incidence of CKD and microalbuminuria (MA) in 2345 participants who attended the sixth Framingham Offspring Study examination (1995 to 1998): C-reactive protein, aldosterone, renin, B-type natriuretic peptide (BNP), plasminogen-activator inhibitor type 1, fibrinogen, and homocysteine. We defined CKD at follow-up (2005 to 2008) as estimated GFR (eGFR) <60 ml/min per 1.73 m²; we defined MA as urine albumin-to-creatinine ratio ≥25 (women) or 17 (men) mg/g on spot urine samples. We identified a parsimonious set of markers related to outcomes adjusting for standard risk factors and baseline renal function, and we assessed their incremental predictive utility. During a mean 9.5-year follow-up, 213 participants developed CKD and 186 developed MA. In multivariable logistic regression models, the multi-marker panel was associated with incident CKD (P < 0.001) and MA (P = 0.003). Serum homocysteine and aldosterone both were significantly associated with CKD incidence, and log-transformed aldosterone, BNP, and homocysteine were significantly associated with incident MA. Biomarkers improved risk prediction as measured by improvements in the c-statistics for both CKD and MA and by a 7% increase in net risk reclassification. In conclusion, circulating homocysteine, aldosterone, and BNP provide incremental information regarding risk for incident CKD and MA beyond traditional risk factors.
Related Concept Videos
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Diabetic Nephropathy
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate